Dr. Lamb is scientific co-founder, Executive Vice President, and Chief Scientific Officer of Incysus Therapeutics. As a transplant immunologist with 27 years? experience in clinical-translational immunotherapy research, he is responsible for first describing the association between relapse-free survival and homeostatic ??T cell recovery in patients with high-risk leukemia following haploidentical bone marrow transplant. While at the University of Alabama at Birmingham, Dr. Lamb developed the scientific support for chemotherapy resistant ??T cell-based immunotherapy for high-grade brain tumors that that has become the foundation of our clinical programs. Dr. Lamb currently leads clinical, translational, and manufacturing strategy and operations for Incysus Therapeutics.